technology
Hosted by Katerina Roznik · technology · EN
Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs.For more content, please subscribe to biotechblueprint.substack.com.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
31%
Guest openness
Selective
Sign up to generate a grounded pitch for Biotech Blueprint.
Signup to Generate a PitchBiotech Blueprint is hosted by Katerina Roznik. The show has published 43 episodes to date.
Recent episodes include "Moderna in 2026: What the Wins and Losses Are Telling Us" (19 May 2026, 54 minutes), "FDA Shifts to One Pivotal Trial and Moderna Flu Shot Back Under FDA Review, This Week in Biotech #90" (20 February 2026, 5 minutes), and "Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars, This Week in Biotech #88" (6 February 2026, 6 minutes).
Biotech Blueprint publishes roughly every two weeks, with episodes averaging 17 minutes across 43 episodes.
Booking probability for Biotech Blueprint is 31%, and the host is rated Selective on guests. Biotech Blueprint requires a Pod Score of 80 or higher. Biotech Blueprint's contact route on record: public web form.
The strongest fits for Biotech Blueprint are Scientific Research & Development. Biotech Blueprint has a technology audience.
Katerina Roznik hosts Biotech Blueprint, a technology podcast with 43 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Biotech Blueprint
Subscribe to Biotech Blueprint for free at biotechblueprint.com In the latest joint podcast episode by Biotech Blueprint × Biotech Capital Compass, we zoom in on Moderna and where the company stands in 2026. We work...
Biotech Blueprint
Subscribe to Biotech Blueprint for free at biotechblueprint.com.
Biotech Blueprint
Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026). Follow Biotech Blueprint at biotechblueprint.com .
Biotech Blueprint
FDA pauses two AAV programs, Sanofi reports US vaccine uptake slipping, and CMS widens negotiations to more blockbuster drugs (Jan 23-29, 2026). Subscribe to Biotech Blueprint at biotechblueprint.com .
Biotech Blueprint
This Week in Biotech #86. Subscribe to Biotech Blueprint for free at biotechblueprint.com . KEYNOTE-942 durability, plus GSK’s $2.2B RAPT food allergy deal, BMS partners with Janux, Corcept's overall survival win, and...
Biotech Blueprint
Subscribe to This Week in Biotech for free at biotechblueprint.com .
Biotech Blueprint
I sat down with NImmune CEO Josep Bassaganya-Riera to talk about omilancor, their gut-restricted oral IBD drug now in Phase 3 clinical trials. We cover LANCL2 biology, their biomarker aimed at boosting response rates...
Biotech Blueprint
Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec 4, 2025). Subscribe to Biotech Blueprint for free at...
Biotech Blueprint
Subscribe to Biotech Blueprint at biotechblueprint.com
Biotech Blueprint
Subscribe to Biotech Blueprint for free at biotechblueprint.com . A week of rare regulatory momentum, strategic M&A, and meaningful clinical wins.
Biotech Blueprint
Subscribe to Biotech Blueprint at biotechblueprint.com In today's episode:How an Oxford-born, YC-backed startup is betting that cell-based production will define mRNA’s next decade.
Biotech Blueprint
Subscribe to Biotech Blueprint for free at biotechblueprint.com . Pfizer’s courtroom gamble to block Novo Nordisk’s $10B Metsera takeover failed, and Novo immediately fired back with an even higher bid, leaving Pfizer...
Biotech Blueprint
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com .
Biotech Blueprint
Subscribe to Biotech Blueprint for FREE at biotechblueprint.com .
Subscribe to Biotech Blueprint for free at biotechblueprint.com . About this episode: mRNA’s next chapter isn’t just flu and COVID. We break down why latent viruses (CMV, EBV, HSV) persist, why T cells matter, and how...
Biotech Blueprint
Subscribe at biotechblueprint.com .
Read the full edition or subscribe to Biotech Blueprint here https://www.biotechblueprint.com/p/pharma-tariffs-on-ice-fda-limits?r=474vk1
Subscribe to Biotech Blueprint newsletter for free at biotechblueprint.com/embed
Biotech Blueprint
Welcome to Biotech Blueprint. If you want to subscribe to a free weekly biotech/pharma newsletter, you can do so here: https://www.biotechblueprint.com/embed In this special episode, I teamed up again with Hartaj from...
Biotech Blueprint
Subscribe to Biotech Blueprint, your free biotech & pharma newsletter released every Friday at biotechblueprint.com
Recent guests on Biotech Blueprint. Study who booked and why before you pitch.
CEO, TotalMed Staffing
NImmune Biopharma
PitchCentric classifies Biotech Blueprint under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
